Clinical Reviews in Allergy & Immunology

, Volume 43, Issue 3, pp 249–255 | Cite as

Impact of Hallmark Autoantibody Reactivity on Early Diagnosis in Scleroderma

  • Pia Moinzadeh
  • Svetlana I Nihtyanova
  • Kevin Howell
  • Voon H Ong
  • Christopher P Denton


Raynaud's phenomenon often precedes the diagnosis of systemic sclerosis and is the first symptom of the disease in many cases. Antinuclear antibody positivity can assist in the early identification of cases of isolated Raynaud's phenomenon likely to progress to systemic sclerosis. However, the specific differences between rate of progression for different scleroderma hallmark antibodies is less clear. We review the predictive potential of ANA positivity and nailfold capillaroscopy for identifying cases of Raynaud's phenomenon which may progress to connective tissue diseases. We also have reviewed data from our own large scleroderma cohort to explore the relationship between antibody subtype and time to development of SSc. Duration of pre-existing Raynaud's phenomenon may be an important determinant of the profile of systemic sclerosis cases identified through screening. Ninety-five percent of our patients with isolated Raynaud's phenomenon, negative autoimmune serology on more than one visit and normal capillaroscopy score showed no progression to connective tissue disease. Duration of antecedent Raynaud's phenomenon differs between disease subsets and scleroderma-specific ANA patterns.


Scleroderma Raynaud Systemic sclerosis Antinuclear antibody 


Competing Interests

The authors declare no competing interest.

Statement of Funding Sources

The on-going clinical research activities in our department are supported by funding from Arthritis Research UK, The Raynaud's and Scleroderma Association and EULAR through the Orphan Diseases Programme. PM was supported by a German ADF/DDG grant.


  1. 1.
    Fransen J, Johnson SR, van den Hoogen F et al (2012) Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res (Hoboken) 64(3):351–357CrossRefGoogle Scholar
  2. 2.
    Johnson SR, Fransen J, Khanna D et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64(3):358–367CrossRefGoogle Scholar
  3. 3.
    Avouac J, Fransen J, Walker UA et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis (VEDOSS): results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70(3):476–481PubMedCrossRefGoogle Scholar
  4. 4.
    Raynaud M 1888: Local Asphyxia and Symmetrical Gangrene of the Extremities 1862. New Researches on the Nature and Treatment of Local Asphyxia of the Extremities 1874. Translated by Barlow T. London: New Sydenham SocietyGoogle Scholar
  5. 5.
    Wigley FM (2002) Clinical practice. Raynaud's phenomenon. N Engl J Med 347(13):1001–1008PubMedCrossRefGoogle Scholar
  6. 6.
    Goundry B, Bell L, Langtree M, Moorthy A (2012) Diagnosis and management of Raynaud's phenomenon. BMJ 344:e289PubMedCrossRefGoogle Scholar
  7. 7.
    Jones GT, Herrick AL, Woodham SE, Baildam EM, Macfarlane GJ, Silman AJ (2003) Occurrence of Raynaud's phenomenon in children ages 12–15 years: prevalence and association with other common symptoms. Arthritis Rheum 48(12):3518–3521PubMedCrossRefGoogle Scholar
  8. 8.
    Suter LG, Murabito JM, Felson DT, Fraenkel L (2005) The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 52(4):1259–1263PubMedCrossRefGoogle Scholar
  9. 9.
    Freedman RR, Mayes MD (1996) Familial aggregation of primary Raynaud's disease. Arthritis Rheum 39(7):1189–1191PubMedCrossRefGoogle Scholar
  10. 10.
    Denton CP, Black CM (2004) Scleroderma—clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271–290PubMedGoogle Scholar
  11. 11.
    LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576PubMedGoogle Scholar
  12. 12.
    Matucci-Cerinic M, Allanore Y, Czirják L et al (2009) The challenge of early systemic sclerosis for the EULAR Scleroderma trial and research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 68(9):1377–1380PubMedCrossRefGoogle Scholar
  13. 13.
    Herrick AL (2005) Pathogenesis of Raynaud's phenomenon. Rheumatol (Oxford) 44(5):587–596CrossRefGoogle Scholar
  14. 14.
    Herrick AL (2011) Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 23(6):555–561PubMedCrossRefGoogle Scholar
  15. 15.
    Galluccio F, Matucci-Cerinic M (2011) Two faces of the same coin: raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev 10(5):241–243PubMedCrossRefGoogle Scholar
  16. 16.
    Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatol (Oxford) 45:iii33–iii35CrossRefGoogle Scholar
  17. 17.
    Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP (2010) Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 103(2):109–115PubMedCrossRefGoogle Scholar
  18. 18.
    Domsic RT, Medsger TA (2012) Disease subsets in clinical practice. In: Varga J, Denton CP, Wigley FM (eds) Scleroderma. From pathogenesis to comprehensive treatment. Springer, New York, pp 45–52Google Scholar
  19. 19.
    Masi AT, Rodnan GP, Medsger TA Jr et al (1980) Subcommittee for scleroderma criteria of american rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRefGoogle Scholar
  20. 20.
    Maricq HR, LeRoy EC (1973) Patterns of finger capillary abnormalities in connective tissue disease by "wide-field" microscopy. Arthritis Rheum 16(5):619–628PubMedCrossRefGoogle Scholar
  21. 21.
    Moore TL, Roberts C, Murray AK, Helbling I, Herrick AL (2010) Reliability of dermoscopy in the assessment of patients with Raynaud's phenomenon. Rheumatol (Oxford) 49(3):542–547CrossRefGoogle Scholar
  22. 22.
    Anders HJ, Sigl T, Schattenkirchner M (2001) Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope. Ann Rheum Dis 60(4):407–409PubMedCrossRefGoogle Scholar
  23. 23.
    Cutolo M, Grassi W, Matucci Cerinic M (2003) Raynaud's phenomenon and the role of capillaroscopy. Arthritis Rheum 48(11):3023–3030, ReviewPubMedCrossRefGoogle Scholar
  24. 24.
    Hoerth C, Kundi M, Katzenschlager R, Hirschl M (2012) Qualitative and quantitative assessment of nailfold capillaries by capillaroscopy in healthy volunteers. Vasa 41(1):19–26PubMedGoogle Scholar
  25. 25.
    Bukhari M, Hollis S, Moore T, Jayson MI, Herrick AL (2000) Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. Rheumatol (Oxford) 39(5):506–512CrossRefGoogle Scholar
  26. 26.
    Nagy Z, Czirják L (2004) Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol 18(1):62–68PubMedCrossRefGoogle Scholar
  27. 27.
    Cutolo M, Pizzorni C, Tuccio M et al (2004) Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatol (Oxford) 43(6):719–726CrossRefGoogle Scholar
  28. 28.
    Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA Jr (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34(1):104–109PubMedGoogle Scholar
  29. 29.
    Graf SW, Hakendorf P, Lester S et al (2012) South Australian scleroderma register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 15(1):102–109PubMedCrossRefGoogle Scholar
  30. 30.
    Mierau R, Moinzadeh P, Riemekasten G et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 13(5):R172PubMedCrossRefGoogle Scholar
  31. 31.
    Hénault J, Tremblay M, Clément I, Raymond Y, Senécal JL (2004) Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. Arthritis Rheum 50:3265–3274PubMedCrossRefGoogle Scholar
  32. 32.
    Villalta D, Tozzoli R, Tonutti E, Bizzaro N (2007) The laboratory approach to the diagnosis of autoimmune diseases: is it time to change? Autoimmun Rev 6(6):359–365PubMedCrossRefGoogle Scholar
  33. 33.
    Reveille JD, Solomon DH, American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49(3):399–412PubMedCrossRefGoogle Scholar
  34. 34.
    Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr (2003) A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48(1):203–209PubMedCrossRefGoogle Scholar
  35. 35.
    Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr (2009) Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 60(4):1112–1118PubMedCrossRefGoogle Scholar
  36. 36.
    Fertig N, Domsic RT, Rodriguez-Reyna T et al (2009) Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 61(7):958–965PubMedCrossRefGoogle Scholar
  37. 37.
    Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr (2005) Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52(8):2425–2432PubMedCrossRefGoogle Scholar
  38. 38.
    Basu D, Reveille JD (2005) Anti-scl-70. Autoimmunity 38(1):65–72PubMedCrossRefGoogle Scholar
  39. 39.
    Walker UA, Tyndall A, Czirják L et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66(6):754–763PubMedCrossRefGoogle Scholar
  40. 40.
    Nihtyanova SI, Denton CP (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 6(2):112–116PubMedCrossRefGoogle Scholar
  41. 41.
    Steen vD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 66:940–944PubMedCrossRefGoogle Scholar
  42. 42.
    Mahler M, Raijmakers R (2007) Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 6(7):432–437PubMedCrossRefGoogle Scholar
  43. 43.
    Penn H, Howie AJ, Kingdon EJ et al (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100(8):485–494PubMedCrossRefGoogle Scholar
  44. 44.
    Ziegler S, Brunner M, Eigenbauer E, Minar E (2003) Long-term outcome of primary Raynaud's phenomenon and its conversion to connective tissue disease: a 12-year retrospective patient analysis. Scand J Rheumatol 32(6):343–347PubMedCrossRefGoogle Scholar
  45. 45.
    Hirschl M, Hirschl K, Lenz M, Katzenschlager R, Hutter HP, Kundi M (2006) Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54(6):1974–1981PubMedCrossRefGoogle Scholar
  46. 46.
    Koenig M, Joyal F, Fritzler MJ et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58(12):3902–3912PubMedCrossRefGoogle Scholar
  47. 47.
    Ingegnoli F, Boracchi P, Gualtierotti R et al (2010) Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatol (Oxford) 49(4):797–805CrossRefGoogle Scholar
  48. 48.
    Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158(6):595–600PubMedCrossRefGoogle Scholar
  49. 49.
    Cutolo M, Pizzorni C, Sulli A (2007) Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: comment on the article by Hirschl et al. Arthritis Rheum 56(6):2102–2103PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Pia Moinzadeh
    • 1
  • Svetlana I Nihtyanova
    • 1
  • Kevin Howell
    • 1
  • Voon H Ong
    • 1
  • Christopher P Denton
    • 1
    • 2
  1. 1.Centre for RheumatologyRoyal Free Hospital and UCL Medical SchoolLondonUK
  2. 2.Centre for Rheumatology and Connective Tissue Diseases, UCL Medical SchoolRoyal Free HospitalLondonUK

Personalised recommendations